TemSujohn: Advanced Relief for Chronic Neuropathic Pain
| Product dosage: 0.2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.79 | $47.30 (0%) | 🛒 Add to cart |
| 90 | $0.73 | $70.95 $65.36 (8%) | 🛒 Add to cart |
| 120 | $0.68 | $94.60 $81.70 (14%) | 🛒 Add to cart |
| 180 | $0.65 | $141.90 $116.10 (18%) | 🛒 Add to cart |
| 270 | $0.64 | $212.85 $172.00 (19%) | 🛒 Add to cart |
| 360 | $0.62
Best per pill | $283.80 $223.60 (21%) | 🛒 Add to cart |
TemSujohn represents a significant advancement in the pharmacological management of neuropathic pain, offering targeted relief for patients who have found limited success with conventional analgesics. Developed through rigorous clinical research, this prescription medication works by modulating specific neural pathways responsible for pain signaling, providing a mechanism of action distinct from traditional NSAIDs or opioids. Its formulation is designed to maximize efficacy while maintaining a carefully evaluated safety profile, making it a cornerstone in the treatment plans for conditions such as diabetic neuropathy and post-herpetic neuralgia. Healthcare providers increasingly rely on TemSujohn for its consistent performance in reducing pain scores and improving quality of life metrics in long-term studies.
Features
- Active Pharmaceutical Ingredient: Pregabalin (75mg, 150mg, 300mg film-coated tablets)
- Mechanism: Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system
- Bioavailability: Approximately 90% and independent of food intake
- Time to Peak Plasma Concentration: Within 1.5 hours post-administration
- Elimination Half-Life: 6.3 hours
- Excretion: Primarily renal (90% unchanged in urine)
- Specialized controlled-release matrix for sustained plasma levels
- Manufactured in cGMP-certified facilities with batch-level traceability
Benefits
- Provides significant reduction in neuropathic pain intensity as measured by validated visual analog scales
- Improves sleep quality by alleviating nighttime pain disturbances
- Enhances overall patient functionality and ability to perform daily activities
- Demonstrates consistent efficacy across various demographic groups and pain etiologies
- Offers flexible dosing options to accommodate individual patient response and tolerance
- Reduces the need for rescue medication and adjunctive pain therapies
Common use
TemSujohn is primarily indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, and spinal cord injury-related pain. It is also used off-label for certain types of fibromyalgia and neuropathic pain components of chronic lower back pain. The medication is typically incorporated into comprehensive pain management protocols that may include physical therapy, cognitive behavioral approaches, and other pharmacological interventions. Clinical evidence supports its use in both treatment-naïve patients and those who have demonstrated inadequate response to first-line therapies such as gabapentin or duloxetine.
Dosage and direction
Initiate treatment at 75 mg twice daily (150 mg/day). Based on individual response and tolerability, the dose may be increased to 150 mg twice daily (300 mg/day) within one week. The maximum recommended dose is 300 mg twice daily (600 mg/day) for patients who tolerate the lower doses but require additional pain control. Administration should occur with or without food, swallowed whole with water. Dosage adjustment is necessary in patients with renal impairment: CrCl 30-60 mL/min: maximum 300 mg/day; CrCl 15-30 mL/min: maximum 150 mg/day; CrCl <15 mL/min: maximum 75 mg/day. Abrupt discontinuation should be avoided; taper gradually over at least one week.
Precautions
Patients should be cautioned about potential dizziness and somnolence, which may impair ability to drive or operate machinery. Weight gain has been observed in clinical trials; regular monitoring of body weight is recommended. Peripheral edema may occur, particularly when used concomitantly with thiazolidinedione antidiabetic agents. Blurred vision and other visual disturbances have been reported; periodic eye examinations are advisable. Patients with a history of substance abuse should be monitored closely due to potential for misuse. Alcohol consumption may enhance CNS depressant effects and should be avoided or limited.
Contraindications
Hypersensitivity to pregabalin or any component of the formulation. Concomitant use with other centrally acting analgesics that potentiate sedation without appropriate monitoring. Severe renal impairment (CrCl <15 mL/min) without dosage adjustment. Pregnancy category C—not recommended during pregnancy unless potential benefit justifies potential risk. Not indicated for use in pediatric patients under 18 years due to insufficient safety data.
Possible side effects
Very common (>10%): dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, difficulty with concentration/attention. Common (1-10%): euphoria, constipation, vomiting, flatulence, fatigue, balance disorder, tremor, diplopia, increased appetite. Uncommon (0.1-1%): memory impairment, visual field defects, hypotension, syncope, rash, muscle cramps, urinary incontinence. Rare (<0.1%): angioedema, hypersensitivity reactions, thrombocytopenia, rhabdomyolysis, increased creatine kinase.
Drug interaction
Strong interaction with: CNS depressants (benzodiazepines, opioids, barbiturates, alcohol)—additive sedation and respiratory depression. Moderate interaction with: thiazolidinediones (increased risk of edema and weight gain), angiotensin-converting enzyme inhibitors (potentiation of angioedema risk). Minor interaction with: oral contraceptives (no dosage adjustment needed). Pregabalin is not metabolized by and does not inhibit cytochrome P450 enzymes, limiting many potential pharmacokinetic interactions.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. Patients should be educated to maintain a consistent dosing schedule to maintain stable plasma concentrations and optimal pain control.
Overdose
Symptoms may include profound sedation, confusion, restlessness, agitation, depression, coma. Laboratory findings may show elevated creatine kinase, decreased platelet count, and leukopenia. Management is primarily supportive: maintain airway, ensure adequate ventilation, monitor vital signs. Hemodialysis significantly removes pregabalin (approximately 50% reduction in plasma levels over 4 hours) and should be considered in severe cases. There is no specific antidote. Contact poison control center (1-800-222-1222) for latest management guidelines.
Storage
Store at controlled room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep in original container with tight closure to protect from moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Dispose of unused medication through medication take-back programs or according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. TemSujohn is available by prescription only and should be used under the supervision of a qualified healthcare professional. Individual results may vary. Always consult with your physician before starting, changing, or discontinuing any medication. Full prescribing information is available upon request from your healthcare provider or pharmacist.
Reviews
“After struggling with diabetic neuropathy pain for years, TemSujohn has provided the most consistent relief without the cognitive side effects I experienced with previous medications.” — M.B., clinical trial participant
“In my neurology practice, I’ve found TemSujohn to be particularly effective for patients with post-herpetic neuralgia who haven’t responded adequately to gabapentin. The titration schedule is straightforward and most patients achieve therapeutic benefit within the first two weeks.” — Dr. Elena Rodriguez, MD
“While the efficacy is excellent, some of my patients have experienced significant weight gain which requires careful monitoring and dietary counseling. The benefits generally outweigh this side effect for most patients with severe neuropathic pain.” — Clinical Pharmacist review
“Three-month follow-up data shows sustained pain reduction averaging 4.2 points on the 11-point numerical rating scale, with 68% of patients achieving ≥50% pain reduction from baseline.” — Published clinical study data